Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Kolltan Pharmaceuticals" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Kolltan Pharmaceuticals for you to read. Along with our medical data and news we also list Kolltan Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Kolltan Pharmaceuticals Companies for you to search.
Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transacti...
European Medicines Agency committee recommends Vivus' Qsiva not be approved - Financings of the Fortnight looks at pending IPOs - Kolltan Pharmaceuticals prepares to move to new stage - Compounding pharmacy association says its position on non-traditional manufacturing is consistent
Edison Investment Research - Pharmaceuticals & healthcare - MGC Pharmaceuticals: Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contrac...
AMAG Pharmaceuticals said today it has agreed to acquire Perosphere Pharmaceuticals for up to $415 million, in a deal that the buyer said will expand its pipeline, and especially its presence in hematology with Perosphere’s next-generation anticoagulant reversal candidate ciraparantag (PER977). Ciraparantag is an intravenously-administered synthetic small molecule anticoagulant reversal agen...
Edison Investment Research - Pharmaceuticals & healthcare - InMed Pharmaceuticals: InMed recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis ...
Barry Labinger has joined Checkmate Pharmaceuticals as president and CEO, the Cambridge, MA, company announced Wednesday. Labinger comes to the cancer drug developer from Biothera Pharmaceuticals, where he was president and CEO. His experience also includes leadership positions at Human Genome Sciences, 3M Pharmaceuticals, and Immunex. Labinger is succeeding Arthur Krieg, who is shifting to [̷...
MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company foc...
BOSTON, MA / ACCESSWIRE / March 6, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tech...
NewsUpon closing of the Proposed Transaction, Nuvo would pay Aralez $110 million in cash,
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m. Astellas made an upfront payment of $164.6m and has...Read More... The post M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals appeared first on Pharmaceutical Tech
Amicus Therapeutics has entered a collaboration with the Perelman School of Medicine at the University of Pennsylvania to develop new...Read More... The post Deals this week: Amicus Therapeutics, Janssen Pharmaceuticals, Ionis Pharmaceuticals appeared first on Pharmaceutical Technology.
AMAG Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc, a private biopharmaceutical company.
Canada-based Bausch Health Companies (previously Valeant Pharmaceuticals) has entered into a definitive agreement to acquire select assets of Synergy Pharmaceuticals...Read More... The post Bausch Health makes $200m bid for bankrupt Synergy Pharmaceuticals appeared first on Pharmaceutical Technology.
Edison Investment Research - Pharmaceuticals & healthcare - Sunesis Pharmaceuticals: In January 2019 Sunesis announced that its Phase Ib/II study of vecabrutinib for B-cell cancers advanced to the ...
Company to Host an Investor Conference Call on Tuesday, March 12, 2019 at 8:00 am EDT BOSTON, MA / ACCESSWIRE / March 12, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotec...
Canada-based Aralez Pharmaceuticals has completed the divestment of more than 20 medicines under its portfolio to Nuvo Pharmaceuticals for a...Read More... The post Aralez completes sale of drug rights to Nuvo Pharmaceuticals for $110m appeared first on Pharmaceutical Technology.
Xellia Pharmaceuticals has entered into an agreement to divest its Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals, a leader of specialty pharmaceutical products with an emphasis on the injectable market
Next Generation Anticoagulant Reversal Agent, Ciraparantag, Will Add Innovative Clinical Stage Asset to AMAG’s Hematology Portfolio Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopha...
December 11 – 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston, MA SVP R&D leading workshop on Financial Planning and Commercial DevelopmentSVP R&D to present A Translational R&D Program with Dronabinol for OSACFO participating on panel on Funding the Commercial Development of Pharmaceutical Cannabinoids Glen Rock, N.J., Dec. 10, 2018 (GLOBE NEW...
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all indications WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage
India-based Glenmark Pharmaceuticals is set to spin-off its innovation business into a new company in the US to increase focus...Read More... The post Glenmark Pharmaceuticals to establish new company in US appeared first on Pharmaceutical Technology.
Nuvo Pharmaceuticals (TSX:NRI,OTCQB:NRIFF) has announced the filing of the business acquisition report on SEDAR related to an acquisition of a portfolio of more than 20 products and associated personnel and infrastructure to continue the products’ management and growth from Aralez Pharmaceuticals. As quoted in the press release: The BAR includes: Audited annual carve-out financial statements...
Edison Investment Research - Pharmaceuticals & healthcare - MGC Pharmaceuticals: Key milestones for MGC Pharmaceuticals in 2019 include the launch of CannEpil sales in Australia, finalising contracts for the construction of a cannabis production and cultivation facility in Malta, and initiation of a Phase II study of CogniCann in dementia. The company has completed the sale of MGC Derma to CannaGl...
King Pharmaceuticals and Acura Pharmaceuticals to seek approval of "abuse deterrent" drug
WALTHAM, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio. Ciraparantag is in development as a single dose, ready-to-use solution for use ...